<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35578211</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2377</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC neurology</Title>
          <ISOAbbreviation>BMC Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rare co-occurrence of multiple sclerosis and Wilson's disease - case report.</ArticleTitle>
        <Pagination>
          <StartPage>178</StartPage>
          <MedlinePgn>178</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">178</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02691-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Wilson's disease is a hereditary disorder of copper metabolism resulting mainly in hepatic, neurological, and psychiatric symptoms. Multiple sclerosis (MS) is an immune-mediated demyelinating disease affecting the central nervous system (CNS). The co-occurrence of these two, although not unheard of in literature, is still considered to be very rare and can give rise to diagnostic difficulties. Also, comorbidity in MS highly influences quality of life and disease progression, which makes the timely diagnosis and treatment of these conditions essential.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">The aim of this study is to present a patient exhibiting symptoms of both MS and Wilson's disease, as well as to conduct a detailed review of previously reported cases. The patient's neurological symptoms (sensory disorder) as well as MRI and CSF findings were characteristic for MS. The diagnosis of MS preceded that of Wilson's disease and was relatively mild in course. Currently, the patient receives cladribine as an immunomodulatory treatment after escalation from glatiramer acetate therapy. Apart from one episode of acute hepatic decompensation, during which transfusion, albumin supplementation and diuretic treatment was necessary, Wilson's disease manifested as chronic impairment of liver function. The diagnosis of Wilson's disease was established by the analysis of serum coeruloplasmin levels, histological examination and genetic findings. Continuous oral penicillamine therapy led to the slow normalization of hepatic function and significant amelioration of the patient's symptoms. Correlating with cases previously reported, the course of MS was relatively mild, and like in three out of four other known cases, the symptoms of Wilson's disease were mostly restricted to hepatic dysfunction.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The case presented in our report is similar to those reported before. The co-occurrence of the two diseases seems to be more a coincidence than a sharing of common factors in their pathogenesis; however, they are considered to influence one another. Regarding rare co-occurrences such as this one, every new case is of high importance, as it enables a better evaluation and understanding of the clinical presentations that are more characteristic of these cases, thus aiding the estimation of disease course as well as possible therapeutic choices.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Despotov</LastName>
            <ForeName>Katalin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Szeged, Faculty of Medicine, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klivényi</LastName>
            <ForeName>Péter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Szeged, Faculty of Medicine, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagy</LastName>
            <ForeName>István</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Internal Medicine I, University of Szeged, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pálvölgyi</LastName>
            <ForeName>Attila</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Internal Medicine I, University of Szeged, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vécsei</LastName>
            <ForeName>László</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Szeged, Faculty of Medicine, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MTA-SZTE Neuroscience Research Group, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Interdisciplinary Excellence Center, University of Szeged, Szeged, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajda</LastName>
            <ForeName>Cecília</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-0252-4778</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Szeged, Faculty of Medicine, Szeged, Hungary. rajda.cecilia@med.u-szeged.hu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Neurol</MedlineTA>
        <NlmUniqueID>100968555</NlmUniqueID>
        <ISSNLinking>1471-2377</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>789U1901C5</RegistryNumber>
          <NameOfSubstance UI="D003300">Copper</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GNN1DV99GX</RegistryNumber>
          <NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006527" MajorTopicYN="Y">Hepatolenticular Degeneration</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010396" MajorTopicYN="N">Penicillamine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">Co-morbidity</Keyword>
        <Keyword MajorTopicYN="N">Multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="N">Point mutation</Keyword>
        <Keyword MajorTopicYN="N">Wilson’s disease</Keyword>
      </KeywordList>
      <CoiStatement>Katalin Despotov has received support for congress participation from Teva. Péter Klivényi has not reported conflict of interest. István Nagy has not reported conflict of interest. Attila Pálvölgyi has not reported conflict of interest. László Vécsei has served as advisory board member and has received support for congress participation or received speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. Cecilia Rajda has received support for congress participation from Roche and Biogen, received honoraria for lecturing from Teva.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>23</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35578211</ArticleId>
        <ArticleId IdType="pmc">PMC9109366</ArticleId>
        <ArticleId IdType="doi">10.1186/s12883-022-02691-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12883-022-02691-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>European Association for the Study of the Liver  EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–685. doi: 10.1016/j.jhep.2011.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2011.11.007</ArticleId>
            <ArticleId IdType="pubmed">22340672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folhoffer A, Ferenci P, Csák T, Horváth A, Hegedûs D, Firneisz G, et al. Genetic and clinical characteristics of Wilson disease in patients from Hungary. Z Gastroenterol. 2008;46(5):A20.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi: 10.1016/S1474-4422(17)30470-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(17)30470-2</ArticleId>
            <ArticleId IdType="pubmed">29275977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–299. doi: 10.1002/ana.21117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21117</ArticleId>
            <ArticleId IdType="pubmed">17444504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61(6):504–513. doi: 10.1002/ana.21141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21141</ArticleId>
            <ArticleId IdType="pubmed">17492755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajda C, Bencsik K, Seres E, Jonasdottir A, Foltynie T, Sawcer S, et al.  A genome-wide screen for association in Hungarian multiple sclerosis. J Neuroimmunol. 2003;143(1–2):84–87. doi: 10.1016/j.jneuroim.2003.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2003.08.017</ArticleId>
            <ArticleId IdType="pubmed">14575920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dzieżyc K, Litwin T, Członkowska A. Multiple sclerosis in two patients with coexisting Wilson’s disease. Mult Scler Relat Disord. 2014;3(3):387–390. doi: 10.1016/j.msard.2013.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2013.09.002</ArticleId>
            <ArticleId IdType="pubmed">25876478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Günther P, Baum P, Then BF. Morbus Wilson und multiple Sklerose. Nervenarzt. 2010;81(2):226–228. doi: 10.1007/s00115-009-2876-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00115-009-2876-0</ArticleId>
            <ArticleId IdType="pubmed">19851743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yetkin MF, Mirza M, Gursoy S. Multiple sclerosis and Wilson disease: a rare coincidence. Clin Neurol Neurosurg. 2019;186:105507. doi: 10.1016/j.clineuro.2019.105507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2019.105507</ArticleId>
            <ArticleId IdType="pubmed">31539738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22366</ArticleId>
            <ArticleId IdType="pmc">PMC3084507</ArticleId>
            <ArticleId IdType="pubmed">21387374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ranjan A, Kalita J, Kumar S, Bhoi SK, Misra UK. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg. 2015;138:31–36. doi: 10.1016/j.clineuro.2015.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2015.07.013</ArticleId>
            <ArticleId IdType="pubmed">26278999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trocello JM, Guichard JP, Leyendecker A, Pernon M, Chaine P, El Balkhi S, et al.  Corpus callosum abnormalities in Wilson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(10):1119–1121. doi: 10.1136/jnnp.2009.204651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.204651</ArticleId>
            <ArticleId IdType="pubmed">20660913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou ZH, Wu YF, Cao J, Hu JY, Han YZ, Hong MF, et al. Characteristics of neurological Wilson’s disease with corpus callosum abnormalities. BMC Neurol. 2019;19(1):1–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhong W, Huang Z, Tang X. A study of brain MRI characteristics and clinical features in 76 cases of Wilson’s disease. J Clin Neurosci. 2019;59:167–174. doi: 10.1016/j.jocn.2018.10.096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2018.10.096</ArticleId>
            <ArticleId IdType="pubmed">30385165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes A, Dedoussis GV. Geographic distribution of ATP7B mutations in Wilson disease. Ann Hum Biol. 2016;43:1–8. doi: 10.3109/03014460.2015.1051492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03014460.2015.1051492</ArticleId>
            <ArticleId IdType="pubmed">26207595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gromadzka G, Schmidt HHJ, Genschel J, Bochow B, Rodo M, Tarnacka B, et al.  p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson’s disease. Mov Disord. 2006;21(2):245–248. doi: 10.1002/mds.20671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20671</ArticleId>
            <ArticleId IdType="pubmed">16211609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3–13. doi: 10.1016/j.neurol.2015.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2015.10.006</ArticleId>
            <ArticleId IdType="pubmed">26718593</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
